List view / Grid view
20 November 2015 | By Victoria White
Health experts are calling on lawmakers to close loopholes in the Orphan Drug Act that, they claim, give drug companies millions of dollars in unintended and misplaced subsidies and tax breaks...
20 November 2015 | By HORIBA Scientific
HORIBA Scientific, global leader in spectroscopic solutions, is pleased to announce that Francis Ndi, current Export Manager, has been promoted to Product Line Manager for the Optical Spectroscopy Division (OSD)...
20 November 2015 | By Victoria White
Baxalta expects to begin treating participants in the open-label, dose-finding study by early 2016...
20 November 2015 | By Victoria White
Orkambi (lumacaftor/ivacaftor), authorised for use in patients who have two copies of the F508del mutation, is the first medicine to treat the underlying cause of cystic fibrosis...
20 November 2015 | By Victoria White
Previously known as SB4, Benepali (etanercept) is a biosimilar candidate to the reference product Enbrel...
20 November 2015 | By Victoria White
The announcement makes Kyprolis (carfilzomib) the first irreversible proteasome inhibitor approved in the EU for use in combination treatment of patients with relapsed multiple myeloma.
19 November 2015 | By Victoria White
In the study, treatment with ALS-00876 resulted in a significant reduction of viral load and faster viral clearance versus placebo...
19 November 2015 | By Victoria White
The new Cancer Drugs Fund will become an instrument for the collection of important information on longer term benefits which may not be available at the time of licensing...
19 November 2015 | By Victoria White
The global atopic dermatitis treatment market will more than double in value from $3.6 billion in 2014 to an estimated $7.3 billion by 2024, according to research and consulting firm GlobalData.
19 November 2015 | By Victoria White
NICE’s FAD coincides with a period of great uncertainty with the Cancer Drugs Fund deliberating again whether to remove radium-223 from the list...
19 November 2015 | By Victoria White
Lilly and Merck are to evaluate the safety and efficacy of the combination of pemetrexed and pembrolizumab in a Phase III study in non-squamous NSCLC...
19 November 2015 | By Victoria White
Earlier this month, Great Ormond Street Hospital (GOSH) reported that UCART19 had been used treat a one-year-old girl who had relapsed acute lymphoblastic leukaemia...
19 November 2015 | By Victoria White
Until this approval, naloxone was only approved in injectable forms, most commonly delivered by syringe or auto-injector...
19 November 2015 | By Victoria White
In the CheckMate -066 trial, Opdivo continued to demonstrate superior overall survival versus dacarbazine with 57.7% of patients alive at two years compared to 26.7% of patients treated with dacarbazine...
18 November 2015 | By Victoria White
Amatuximab is a monoclonal antibody (mAb) that triggers antibody-dependent cellular cytotoxicity against tumour cells expressing mesothelin...
